Inhibiting Cancer Angiogenesis With Molecular Therapy

摘要: An exciting approach in cancer molecular therapy is the ability to target developing blood supply of tumor. In contrast several other approaches, antiangiogenic can readily access its target—the tumor vasculature. Numerous viral and nonviral vectors that angiogenesis have demonstrated antitumor efficacy preclinical models vivo. Molecular strategies inhibit proangiogenic growth factors such as vascular endothelial factor (VEGF) or receptors include antisense methods, RNAzymes, DNAzymes, RNAi, a dominant-negative protein encoded from gene. These therapeutic molecules could be incorporated within mammalian expression (plasmids viruses) and/or delivered small polynucleotide molecules. Alternatively, inhibited by vivo “endogenous” proteins peptides thrombospondin 1 2. this chapter, we discuss current status therapy.